VCs Compare Notes On Biotech Investment Landscape In 2016
This article was originally published in Scrip
Executive Summary
So far in 2016 the number and value of deals by pharma and biotech companies in the private sector has dropped significantly compared to recent years – but money is still there for start-ups with innovative technology and robust science, say venture capitalists.